4275 EXECUTIVE SQUARE, LA JOLLA, CA
News, Articles of Incorporation, Bylaws
Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
To Acquire Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
Investor Presentation
News, Articles of Incorporation
Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Q3
Q2
Q1
FY 2023
FY 2022
Notice of Suspension of Duty to File Reports
Effectiveness Notice
RW
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Automatic Shelf Registration Statement
RW WD
S-8 POS